Objective. Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that 17 is difficult to treat. There is currently no optimal stratification of patients with SLE, and thus 18 responses to available treatments are unpredictable. Here, we developed a new stratification 19 scheme for patients with SLE, based on the whole-blood transcriptomes of patients with SLE. 20
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INTRODUCTION 51
Systemic lupus erythematosus (SLE) is a debilitating chronic autoimmune condition 52 characterised by the activation of inflammatory immune cells and the production of pro-53 inflammatory autoantibodies responsible for pathology in multiple organs.
1 SLE is highly 54 heterogeneous, and can be seen as a syndrome rather than a single disease. 2 The responsiveness 55 of patients to available treatments is variable and difficult to predict. Rather than a small 56 number of highly associated loci, over 60 SLE low-association loci have been identified by 57 genome-wide association studies.
3-6 SLE has been studied using numerous useful mouse 58 models, each of which manifest SLE-like symptoms underpinned by different molecular 59 mechanisms. Two examples are mice overexpressing B cell activating factor of the TNF family 60 (BAFF, also known as TNFSF13B) i.e. BAFF-transgenic mice, in which low-affinity self-61 reactive B cells aberrantly survive, 7, 8 and glucocorticoid-induced leucine zipper (GILZ)-62 deficient mice 9 with impaired regulation of activated B cells. These and various other mouse 63 models of SLE replicate some aspects of disease relevant to some patients with SLE, but most 64 likely do not individually account for all the disease symptoms and pathogenesis mechanisms 65 in humans. 66
67
Numerous large-scale clinical trials for SLE treatments have been carried out, with an 68 improvement over standard of care as the expected outcome of these studies. Disappointingly, 69 the vast majority of tested therapies failed their primary endpoints, 10 except belimumab, an 70 inhibitor of the cytokine BAFF, showing modest efficacy in a subset of patients with SLE.
11
(sPLS-DA) was performed using the mixOmics R package (using Lasso penalisation to rank 127 predictive genes), 24 and the MUVR R package (v.0.0.971). 25 Cross-validation was used to 128 protect against overfitting: in mixOmics, using M-fold cross-validation (10-folds averaged 50 129 times); in MUVR, using 15 repetitions of repeated double cross-validation (rdCV). A repeated 130 measures design was used when combining datasets. 26 Unsupervised clustering was performed 131 with MATLAB (MathWorks), using the k-means function (using 100 repetitions to optimise 132 initial centroid positions). Error-correcting output codes (ECOC) classifiers, which contain 133 several support vector machines for multi-class identification, were generated using 134 MATLAB. Random forest classifiers were generated using MUVR. 
Count-based expression analyses 138
The limma/edgeR workflow was used for differential expression analysis. 22 The EGSEA 139 (v1.10.1) R package was used to statistically test for enrichment of gene expression sets, using 140 a consensus of several gene set enrichment analysis tools.
27 EGSEA uses count data 141 transformed with voom (a function of the limma package). 28 Collections of pre-defined gene 142 sets were from KEGG Pathways, and the Molecular Signatures Database (MSigDB: "H", "c2", 143
and "c5" collections).
29

145
Circulating immune cell composition analysis 146
Flow cytometry 147
Whole blood samples collected into lithium heparin tubes (BD) were examined for frequency 148 of circulating neutrophils (CD16 + , CD49d -) by flow cytometry, using an LSR Fortessa 149 instrument (BD Biosciences), and FlowJo software (Tree Star), as previously described. 
Statistical Analysis 158
The mixOmics and MUVR R packages were used for multivariate analysis using count data. 32 159 R version 3.5.2 was used. Kruskal-Wallis tests (with Dunn's correction for multiple 160 comparisons) and Mann-Whitney tests were performed using Prism software (v8.0.2, 161 GraphPad). Statistically significant differences are shown for p < 0.05 (*), p < 0.01 (**), p < 162 0.001 (***); p < 0.0001 (****); or not significant (n.s.). 163
164
RESULTS
165
We examined our cohort of 30 patients with SLE and 29 healthy donors for differentially 166 expressed genes by RNA-seq, alongside two other publicly available datasets (141 SLE and 51 167 healthy donor whole-blood transcriptomes in total). Principal components analysis (PCA), 168 which looks at all gene expression and visualises the overall variance between individuals, 169 suggests a higher gene expression heterogeneity in SLE samples than healthy controls, which 170 projected more closely together ( figure 1A ). Gene expression in some SLE samples was similar 171 to that of healthy controls. Supervised clustering (to draw apart the groups) was performed 172 using sparse partial least squares discriminant analysis (sPLS-DA). This method selected a 173 subset of discriminating genes that are more useful for separating healthy and SLE patients 174 ( figure 1B ). An expression heatmap using the top-ranking discriminating genes shows 175 heterogeneity across patients with SLE ( figure 1C ), but visually demonstrates the possibility 176 of organising SLE patients into several discrete clusters. 177
178
We applied unsupervised k-means clustering to group patients into four clusters, C1-C4; 179
Clusters were visualised with a PCA plot ( figure 2A ). The k-means clustering algorithm uses 180 a chosen number of cluster centroids, which are repositioned among the samples until 181 convergence.
33 Supervised machine learning was applied, confirming that classification 182 software can be trained to learn the transcriptomic signatures of each cluster and accurately 183 classify new patients (88% accuracy, supplementary figures S2-3, using two different classifier 184 algorithms). In comparing the expression levels of several well-established SLE-associated genes in SLE 215 clusters, we found evidence that different pathogenesis pathways were associated with each 216 cluster of patients. BAFF (TNFSF13B) overexpression is well-established as a driver of 217 autoimmunity, 7 targeted by belimumab. Interestingly, high BAFF expression is a very 218 significant feature of C4 and to a lesser magnitude C2, but not C1 and C3 (figure 4A). TNFSF10 219 mRNA (encoding the apoptosis-inducing ligand TRAIL) expression is also upregulated in 220 SLE, 35 and this mirrors elevated BAFF expression in C4 and C2 (figure 4B 
4D). PELI1 (encoding 233
Pellino1) is a TLR3-inducible negative regulator of noncanonical NF-kB and the expression 234 of PELI1 was negatively correlated with disease severity. 39, 40 In our stratification, PELI1 is 235 not significantly under-expressed in any SLE clusters, but is upregulated in C3 and C4, possibly 236 induced for NF-kB regulation (figure 4E). TSC22D3 (also known as GILZ) was identified as a 237 negative regulator of B cells and lack of GILZ can drive autoimmune disease.
9 GILZ expression 238 was markedly diminished in C2, suggesting a loss of B cell regulation. GILZ was upregulated 239 in C3 and C4, possibly as an effect of glucocorticoid induction ( figure 4E) . Metric (ISM) is a composite score of mRNA expression from three interferon-regulated genes 250 (HERC5, CMPK2, and EPSTI1).
41 Expression of these genes was consistently upregulated in 251 C2 and C4, whereas C3 levels were comparable to that of healthy donors. Patients in C1 had 252 variable levels with only the expression of HERC5 but not the other ISM genes being 253 significantly increased relative to healthy controls ( figure 4G-I) . 254
255
In Dataset 2, 6 of the 30 patients with SLE had flares, who diverged further from healthy donors 256 when visualised by PCA ( figure 5A ). Using sPLS-DA to select flare-discriminating genes 257
(figure 5B), we found differential gene expression during flares to be consistent with increased 258 innate activation and altered immune cell regulation ( figure 5C-F) . Indeed, the RETN gene, 259 encoding the proinflammatory adipokine Resistin, is upregulated in patients with active flares 260 only ( figure 5C ). Resistin is linked to proinflammatory cytokine induction. 42 Significant 261 downregulation of TCL1A and PAX5 ( figure 5D-E the pharmaceutical sector to more rigorously assess the reasons for this high failure rate. 276
Suggested factors include issues with the design of clinical trials, difficulty in defining robust 277 endpoints, non-ideal drug targets and biomarkers, and, high heterogeneity of study 278 populations.
10 Large-scale clinical trials invariably fail to demonstrate efficacy when enrolling 279 patients selected on a limited number of clinical criteria, which do not capture the underlying 280 molecular mechanism likely underpinning disease, which varies greatly in patients (figures 2-281 3). Inclusion of some patients with low disease propensity (C1) further weakens comparisons 282 between placebo and experimental treatment groups. 283
284
Our stratification method captures the likely underlying disease mechanism, using whole-blood 285 transcriptomics to obtain a snapshot of the immune system. This stratification could be very 286 useful for the improved design of clinical trials, by more appropriately targeting specific 287 clusters of patients with SLE who are much more likely to have a homogenous mechanism of 288 action underpinning pathology (figures 2B,4). Retrospective analysis of previous failed trials 289 could reveal high efficacy in specific clusters of patients, which was not possible to see in an 290 unstratified analysis. Successful off-label usage of rituximab in some patients with SLE further 291 suggests therapies that have failed in clinical trials with SLE may yet have efficacy in selected 292 patients. 49, 50 Indeed, looking at the expression levels of key drug-targeted molecules such as 293 BAFF and CD40L suggests that certain clusters of patients might be much better fit for the 294 rationale of targeted biologics than other clusters (figure 4). 295 296 Similar to us, previous studies using microarrays have encountered distinct clusters of SLE 297 patients in whole-blood transcriptome data. 51, 52 In this study, we used RNA-seq data, which 298 has the advantages of capturing additional genes (not restricted to probe sets) and improved 299 dynamic range. Additional systems biology approaches (such as microbial metagenomics, and 300 metabolomics) are becoming available in SLE, and combining matching data from additional 301 profiling methods may allow for improved sets of clinically useful biomarkers.
53-56
303
Transient flare activity in SLE patients causes a significant surge in inflammation requiring 304 medical attention, but much remains to be understood about the underlying molecular basis 305 and transcriptomic features of flare activity. We identified several flare-associated genes 306 including the RETN gene, encoding the proinflammatory adipokine resistin ( figure 5C ). 307
Interestingly, serum resistin levels are elevated in patients with rheumatoid arthritis and/or SLE 308 patients, although the differences were reported not significant in unstratified patients with 309 SLE, where high heterogeneity was noted. 57 The specificity of elevated resistin levels to flare-310 active patients may explain these results. Taking this further, longitudinal studies would be 311 useful for discovering flare-predicting transcriptional signatures, which may be used as 312 prognostic markers alerting patients and physicians of an increased risk of flares under their 313 current treatment plan. 314
315
The IFN gene signature was associated with patients with SLE, although this feature does not 316 correlate well with overall disease severity.
41 Stratification of ISM-high patients is possible 317 using qPCR assays for the gene expression of three genes in peripheral blood, 41 which in our 318 stratification corresponds to C2 and C4 ( figure 2B, 4H-L In conclusion, our study provides new insights into the heterogeneity of patients with SLE with 324 respect to gene expression in circulating immune cells, as the messengers of overall immune 325 activity in individual patients. Our approach using whole-blood transcriptomics data combined 326 with machine learning approaches is powerful at segregating and recognising patient clusters, 327 uncovering cluster-specific gene expression patterns linked to known pathogenesis features. 328
Optimal patient stratification is critically lacking in clinical trials for SLE, for which success 329 rates and cost-effectiveness can be greatly improved by more robustly targeting the most 330 relevant clusters of patients. Further development of machine-learned classifiers and validation 331 of their utility using matching data on patients' response to specific therapies, may deliver new 332 clinical tools assisting with better treatment decisions for individual patients. after clustering using the k-means algorithm. Four clusters of patients were segregated and 545 displayed with different symbols. Three datasets were combined (see Table 1 Table 1 ). Significant differences 566 (detailed in methods) between healthy and SLE samples are indicated. accuracy of the classifier was tested using independent cases from Datasets 2+3, checking 587 whether the cluster identification matches the original clustering by k-means in figure 2. 588 589 Figure S3 . SLE subset discrimination using random forest classifiers. Three whole-blood 590 RNA-seq datasets encompassing 141 patients with SLE were clustered (as in figure 1) .
(A) 591
Random forest classifiers were trained and tested using repeated double cross validation to 592 protect from overfitting, while selecting optimal gene sets with predictive value, using the 593 minimum number of genes ('min'), maximum number of genes with predictive value ('max'), 594 or the geometric mean from those models ('mid'). Using very few genes (on the left of this plot) 595 results in a higher error rate; using too many genes with no added predictive value (on the right 596 side of this plot) also results in a higher error rate due to the accumulation of noise. (B) 597
Performance testing of the 'mid' classification model, which had 88% overall accuracy to 598 predict the original cluster type, using 49 genes. 
